Rakovina Therapeutics announces successful results from 2025 annual general meeting

From GlobeNewswire: 2025-06-25 18:17:00

Rakovina Therapeutics Inc. announced the results of voting at its 2025 annual general meeting of shareholders. All five board of director nominees were elected, including Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia, Yevgeniy Meshcherekov, and Dr. David Kideckel. Shareholders also approved the re-appointment of the auditor, set the number of directors to five, and re-approved the existing omnibus equity incentive plan. Rakovina Therapeutics focuses on developing cancer treatments using AI-powered drug discovery, aiming to advance drug candidates into human clinical trials through collaboration with pharmaceutical partners.



Read more at GlobeNewswire: Rakovina Therapeutics Announces Results from 2025 Annual